Nivolumab en/of ipilimumab en totale overleving in gevorderd melanoom? - Skin
Presented By Michael Overman at 2016 ASCO Annual Meeting - ppt video online download
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Targeting Programmed Death-1 (PD-1) and Its Ligand (PD-L1) | Personalized Medicine in Oncology
Special Issues | Value-Based Cancer Care
Nieuwe behandelingen in de oncologie: immunotherapie en TKI s, veiligheid en interacties Een keerzijde van nieuwe immuuntherapieen? - PDF Free Download
Synergism between CTLA-4 and PD-(L)1 inhibition: the nivolumab-ipilimumab story - BJMO
Targets and action of ICIs ipilimumab, nivolumab, and pembrolizumab: A.... | Download Scientific Diagram
Ipilimumab - Yervoy blijkt veilige en effectieve behandeling bij beginnende nog niet behandelde patienten met een melanoom.
Frontiers | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time | Immunology
IJMS | Free Full-Text | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials | HTML
New modalities of cancer treatment for NSCLC: focus on immunotherapy | CMAR
Home - UROONCO Kidney Cancer
Ipilimumab: Mode of Action Note. From " Ipilimumab: Controversies in... | Download Scientific Diagram
Cancers | Free Full-Text | The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma | HTML
Nivolumab Overview - Creative Biolabs
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Ipilimumab – mechanism of action and impact on advanced melanoma - ppt download
IJMS | Free Full-Text | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials | HTML
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 - Annals of Oncology
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Mechanism of action of nivolumab. | Download Scientific Diagram
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings | RadioGraphics
